ARK Reports 6.42% GeneDx Stake Without Seeking To Influence Company Control

The investment manager's report covered 1,913,123 common shares held as of September 30.

Share
ARK Reports 6.42% GeneDx Stake Without Seeking To Influence Company Control

ARK Investment Management reported a 6.42% stake in GeneDx, which uses genetic testing to help diagnose genetic diseases, in an SEC ownership amendment filed Friday. The position covered 1,913,123 common shares as of September 30, with ARK certifying that the holding was not intended to change or influence company control.

Voting Authority And Wood's Role

ARK had sole voting authority over 1,815,108 shares and shared voting authority over 26,835 shares. It reported sole authority to dispose of all 1,913,123 shares.

Catherine D. Wood, ARK's chief executive and chief investment officer, joined the report under a joint filing agreement. Her reporting row covered the same 1,913,123 shares and 6.42% stake, with shared voting authority over 1,841,943 shares and no sole voting authority.

The passive ownership certification said the securities were bought and held as part of ordinary business. That certification addresses the holding's purpose: changing or influencing control was not its objective.

A Genetic-Testing Holding In ARK's Portfolio

ARK's exchange-traded funds hold concentrated positions in small and midsize companies. Those holdings frequently pass the 5% ownership threshold; the manager submitted about 170 ownership schedules over two years.

GeneDx's ExomeDx test examines protein-coding DNA, while GenomeDx examines the whole genome, looking for genetic changes that may cause disease. Its diagnostic work particularly serves children with rare disorders.

Substantially all of GeneDx's 2025 revenue came from diagnostic test reports. Payments come from insurers and other third-party payors, patients, business clients and healthcare partners.

The company's 2025 annual-report profile described a team of nearly 1,300 people. Its GeneDx Infinity dataset draws on over 2.5 million tests, including over 1 million exomes and genomes, to help interpret patients' results.

GeneDx had a market value of about $1.6 billion in Friday trading as of 12:54 p.m. ET.

Sources

More on GeneDx

All GeneDx (WGS) coverage →